Please assess the completion status of the following clinical trial:

Trial Title: Bio-availability of Rectal Artesunate in Children With Severe Falciparum Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Weight ≥6 kilograms and ≤ 34 kilograms~* Severe malaria (WHO Guidelines 2013; Appendix 1)~* P. falciparum infection confirmed by Rapid Diagnostic Test (P. falciparum monoinfection or mixed infection with P. ovale or P. malariae)~* Parents or guardian signed Informed Consent~Exclusion Criteria:~* Acute diarrhoea defined as \> 3 liquid stools in the previous 24 hours~* Visible anorectal malformations or a disease of the rectum~* Known hypersensitivity to quinine or artesunate~* A documented history of an effective dose of parenteral antimalarial in the preceding 24 hours or a single dose of rectal artesunate in the previous 12 hours or a dose of an artemisinin based combination therapy in the previous 6 hours~* Co-morbidity which in the judgement of the investigator would interfere with the patient treatment or results of the study or place the subject at undue risk~* Participation in another clinical trial or earlier in the same clinical trial

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IR artesunate + IV artesunate (Type: EXPERIMENTAL): Patients receive 1 dose of intrarectal artesunate (10 mg/ kg b.w.) on admission and 1 dose of intravenous artesunate (2.4 mg/kg body weight) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.
- IV artesunate + IR artesunate (Type: EXPERIMENTAL): Patients receive 1 dose of intravenous artesunate (2.4 mg/kg b.w) on admission and 1 dose of intrarectal artesunate (10 mg/ kg b.w.) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.

Based on this trial design, predict the completion outcome and termination type (if applicable).